Preinvasive  ||| S:0 E:12 ||| FW
lesions  ||| S:12 E:20 ||| FW
in  ||| S:20 E:23 ||| FW
gynaecology -   ||| S:23 E:38 ||| FW
endometrium  ||| S:38 E:50 ||| FW
Preinvasive  ||| S:50 E:62 ||| FW
lesions  ||| S:62 E:70 ||| FW
of  ||| S:70 E:73 ||| IN
the  ||| S:73 E:77 ||| DT
endometrium  ||| S:77 E:89 ||| NNS
are  ||| S:89 E:93 ||| VBP
histopathological  ||| S:93 E:111 ||| VBN
and  ||| S:111 E:115 ||| CC
molecular  ||| S:115 E:125 ||| JJ
alterations  ||| S:125 E:137 ||| NNS
related  ||| S:137 E:145 ||| VBN
to  ||| S:145 E:148 ||| TO
high-risk  ||| S:148 E:158 ||| JJ
of  ||| S:158 E:161 ||| IN
uterine  ||| S:161 E:169 ||| JJ
carcinoma  ||| S:169 E:179 ||| JJ
development ||| S:179 E:190 ||| NN
.  ||| S:190 E:192 ||| .
Incidence  ||| S:192 E:202 ||| NNP
has  ||| S:202 E:206 ||| VBZ
increasing  ||| S:206 E:217 ||| VBG
tendency ||| S:217 E:225 ||| NN
.  ||| S:225 E:227 ||| .
Atypical  ||| S:227 E:236 ||| FW
endometrial  ||| S:236 E:248 ||| FW
hyperplasia  ||| S:248 E:260 ||| FW
is  ||| S:260 E:263 ||| VBZ
the  ||| S:263 E:267 ||| DT
preinvasive  ||| S:267 E:279 ||| JJ
lesion  ||| S:279 E:286 ||| NN
of  ||| S:286 E:289 ||| IN
type  ||| S:289 E:294 ||| NN
I  ||| S:294 E:296 ||| PRP
endometrial  ||| S:296 E:308 ||| VBP
carcinoma ||| S:308 E:317 ||| VBN
,  ||| S:317 E:319 ||| ,
developing  ||| S:319 E:330 ||| VBG
under  ||| S:330 E:336 ||| IN
a  ||| S:336 E:338 ||| DT
hyperestrogenic  ||| S:338 E:354 ||| JJ
background ||| S:354 E:364 ||| NN
.  ||| S:364 E:366 ||| .
Carcinoma  ||| S:366 E:376 ||| NNP
in  ||| S:376 E:379 ||| IN
situ  ||| S:379 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
the  ||| S:387 E:391 ||| DT
endometrium  ||| S:391 E:403 ||| NN
is  ||| S:403 E:406 ||| VBZ
considered  ||| S:406 E:417 ||| VBN
to  ||| S:417 E:420 ||| TO
be  ||| S:420 E:423 ||| VB
precursor  ||| S:423 E:433 ||| JJ
lesion  ||| S:433 E:440 ||| NN
of  ||| S:440 E:443 ||| IN
type  ||| S:443 E:448 ||| NN
II  ||| S:448 E:451 ||| NNP
endometrial  ||| S:451 E:463 ||| JJ
carcinoma ||| S:463 E:472 ||| NN
,  ||| S:472 E:474 ||| ,
first  ||| S:474 E:480 ||| JJ
of  ||| S:480 E:483 ||| IN
all  ||| S:483 E:487 ||| DT
uterine  ||| S:487 E:495 ||| JJ
serous  ||| S:495 E:502 ||| JJ
carcinoma ||| S:502 E:511 ||| NN
.  ||| S:511 E:513 ||| .
Hysterectomy  ||| S:513 E:526 ||| NNP
and  ||| S:526 E:530 ||| CC
bilateral  ||| S:530 E:540 ||| JJ
oophorectomy  ||| S:540 E:553 ||| NN
is  ||| S:553 E:556 ||| VBZ
the  ||| S:556 E:560 ||| DT
main  ||| S:560 E:565 ||| JJ
therapeutical  ||| S:565 E:579 ||| JJ
modality  ||| S:579 E:588 ||| NN
in  ||| S:588 E:591 ||| IN
both  ||| S:591 E:596 ||| DT
preinvasive  ||| S:596 E:608 ||| JJ
lesions  ||| S:608 E:616 ||| NNS
of  ||| S:616 E:619 ||| IN
the  ||| S:619 E:623 ||| DT
endometrium ||| S:623 E:634 ||| NN
.  ||| S:634 E:636 ||| .
The  ||| S:636 E:640 ||| DT
hormonal  ||| S:640 E:649 ||| JJ
therapy  ||| S:649 E:657 ||| NN
with  ||| S:657 E:662 ||| IN
progestogens  ||| S:662 E:675 ||| NN
is  ||| S:675 E:678 ||| VBZ
the  ||| S:678 E:682 ||| DT
possibility  ||| S:682 E:694 ||| NN
of  ||| S:694 E:697 ||| IN
fertility  ||| S:697 E:707 ||| JJ
sparing  ||| S:707 E:715 ||| JJ
approach  ||| S:715 E:724 ||| NN
in  ||| S:724 E:727 ||| IN
treatment  ||| S:727 E:737 ||| NN
of  ||| S:737 E:740 ||| IN
histological  ||| S:740 E:753 ||| JJ
findings  ||| S:753 E:762 ||| NNS
of  ||| S:762 E:765 ||| IN
atypical  ||| S:765 E:774 ||| JJ
endometrial  ||| S:774 E:786 ||| JJ
hyperplasia  ||| S:786 E:798 ||| NN
in  ||| S:798 E:801 ||| IN
young  ||| S:801 E:807 ||| JJ
women ||| S:807 E:812 ||| NNS
.  ||| S:812 E:814 ||| .
Even  ||| S:814 E:819 ||| RB
though  ||| S:819 E:826 ||| IN
preinvasive  ||| S:826 E:838 ||| JJ
lesions  ||| S:838 E:846 ||| NNS
of  ||| S:846 E:849 ||| IN
the  ||| S:849 E:853 ||| DT
endometrium  ||| S:853 E:865 ||| NNS
are  ||| S:865 E:869 ||| VBP
clearly  ||| S:869 E:877 ||| RB
defined ||| S:877 E:884 ||| VBN
,  ||| S:884 E:886 ||| ,
the  ||| S:886 E:890 ||| DT
possibilities  ||| S:890 E:904 ||| NNS
of  ||| S:904 E:907 ||| IN
endometrial  ||| S:907 E:919 ||| JJ
cancer  ||| S:919 E:926 ||| NN
screening  ||| S:926 E:936 ||| NNS
are  ||| S:936 E:940 ||| VBP
markedly  ||| S:940 E:949 ||| RB
limited ||| S:949 E:956 ||| VBN
.  ||| S:956 E:958 ||| .
